Kyverna Therapeutics Announces Collaboration with Charité to Fund Research into B Cell and Plasma Cell-Targeting Therapies in Patients with Autoimmune Diseases

Kyverna Therapeutics announced the signing of a multi-year research funding agreement with Charité – Universitätsmedizin Berlin to investigate the impact of B- and plasma cell-targeting therapies – including CAR T cells – on the immunologic profile and clinical outcomes of patients with systemic autoimmune diseases.